Mustang Bio Presents Favorable Phase 1/2 MB-106 Clinical Trial Data at EHA2024
DENVER, Colo., Jun 17, 2024 (247marketnews.com)- Mustang Bio, Inc. (Nasdaq:MBIO) presented positive updated data from its ongoing Phase 1/2 MB-106, a CD20-targeted, autologous CAR T-cell therapy, clinical trial, which shows a favorable safety and efficacy profile in patients with Waldenstrom macroglobulinemia (“WM”), a rare form of blood cancer, at the European Hematology Association 2024 Hybrid Congress (EHA2024).
Brian Till, M.D., Associate Professor and physician at Fred Hutch and University of Washington, stated, “We are very encouraged by the safety and efficacy data generated in WM, along with improvements in the quality of responses over time, which demonstrates MB-106 CAR T-cell expansion and persistence.”
About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.
24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.
CONTACT:
24/7 Market News
Editor@247marketnews.com
Related news for (MBIO)
- MoBot alert highlights: NASDAQ: BMGL, NASDAQ: MBIO, NASDAQ: ENTO, NASDAQ: AQMS, NYSE: CLDI (07/09/25 06:00 AM)
- Breaking News: MoBot’s Latest Update as of 07/07/25 09:00 AM
- Market Headliners– July 7, 2025
- MoBot alert highlights: NASDAQ: MBIO, NYSE: LGPS, NASDAQ: SONN, NASDAQ: MULN, NASDAQ: CURR (07/07/25 08:00 AM)
- Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-101 (IL13Ra2-targeted CAR T-cells) to Treat Astrocytomas and Glioblastoma